Literature DB >> 17496544

Anti-LFA-1 improves pig islet xenograft function in diabetic mice when long-term acceptance is induced by CTLA4Ig/anti-CD40L.

Makiko Kumagai-Braesch1, Henrik Ekberg, Feng Wang, Cecilia Osterholm, Cecilia Ehrnfelt, Amit Sharma, Ellinor Lindeborg, Jan Holgersson, Matthias Corbascio.   

Abstract

BACKGROUND: It has been previously demonstrated that addition of anti-LFA-1 to a combination of CTLA4Ig and anti-CD40L induces the permanent acceptance of dopaminergic fetal pig xenografts when transplanted into the brain of wild-type mice. The purpose of this study was to test whether this costimulation blockade also can induce acceptance of adult pig islets transplanted to C57BL/6 mice with streptozotocin-induced diabetes.
METHODS: Recipients were treated with CTLA4Ig/anti-CD40L+/-anti-LFA-1 or isotype control antibodies during the first week after transplantation. Half of the costimulation blockade-treated recipients had their grafts removed after 8 weeks. The other half was observed up to 5 months.
RESULTS: Recipients treated with CTLA4Ig/anti-CD40L/anti-LFA-1 had significantly lower blood glucose and gained more weight than CTLA4Ig/anti-CD40L-treated recipients. CTLA4Ig/anti-CD40L-treated recipients exhibited unstable blood glucose. IPGTT of these recipients revealed a slow recovery to normal blood glucose levels at week 4. In comparison, CTLA4Ig/anti-CD40L/anti-LFA-1 treated recipients exhibited a significantly superior glucose clearance. CTLA4Ig/anti-CD40L+/-anti-LFA-1 treated recipients did not produce anti-pig IgG, whereas control antibody-treated mice did. CD4+ T cells from costimulation blockade-treated recipients proliferated less than CD4+ T cells from control antibody-treated mice when co-cultured with syngeneic antigen presenting cells loaded with pig islet antigens.
CONCLUSIONS: CTLA4Ig/anti-CD40L/anti-LFA-1-treated recipients had superior islet function compared with CTLA4Ig/anti-CD40L-treated recipients. However, both costimulation blockade regimens led to islet graft acceptance up to 5 months after a 1-week treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17496544     DOI: 10.1097/01.tp.0000261722.02697.75

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Effect of triple costimulation blockade on islet allograft survival in sensitized mice.

Authors:  R Diab; T Iwata; M Corbascio; A Tibell; H Ekberg; J Holgersson; M Kumagai-Braesch
Journal:  Transplant Proc       Date:  2010 Jul-Aug       Impact factor: 1.066

2.  Corticosteroids and methotrexate as adjuvants to costimulation blockade in non-human primate renal transplantation.

Authors:  Douglas J Anderson; Denise J Lo; Francis Leopardi; Mingqing Song; Elizabeth A Strobert; Joe B Jenkins; Christian P Larsen; Allan D Kirk
Journal:  Clin Transplant       Date:  2019-05-07       Impact factor: 2.863

3.  Inhibition of recall responses through complementary therapies targeting CD8+ T-cell- and alloantibody-dependent allocytotoxicity in sensitized transplant recipients.

Authors:  Jason M Zimmerer; Phillip H Horne; Lori A Fiessinger; Mason G Fisher; Kartika Jayashankar; Sierra F Garcia; Mahmoud Abdel-Rasoul; Nico van Rooijen; Ginny L Bumgardner
Journal:  Cell Transplant       Date:  2012-10-11       Impact factor: 4.064

4.  Pig embryonic pancreatic tissue as a source for transplantation in diabetes: transient treatment with anti-LFA1, anti-CD48, and FTY720 enables long-term graft maintenance in mice with only mild ongoing immunosuppression.

Authors:  Dalit Tchorsh-Yutsis; Gil Hecht; Anna Aronovich; Elias Shezen; Yael Klionsky; Chava Rosen; Rivka Bitcover; Smadar Eventov-Friedman; Helena Katchman; Sivan Cohen; Orna Tal; Oren Milstein; Hideo Yagita; Bruce R Blazar; Yair Reisner
Journal:  Diabetes       Date:  2009-04-28       Impact factor: 9.461

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.